Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
GAITHERSBURG, Md., Dec. 08, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference.
Conference details are as follows:
Date: Tuesday, December 15, 2015
Forum: One-on-one meetings
Location: The Langham Boston, Boston, MA
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
